Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SCPX

Scorpius Holdings Inc.

Oct 04 • 01:19PM ET

0.7500

Dollar change +0.0190
Percentage change 2.60	%

Healthcare • Biotechnology • USA • AMEX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-200.40	Insider Own	10.54%	Shs Outstand	3.12M	Perf Week	2.74%
Market Cap	2.34M	Forward P/E	-	EPS next Y	-2.91	Insider Trans	0.00%	Shs Float	2.79M	Perf Month	-9.64%
Income	-31.83M	PEG	-	EPS next Q	-	Inst Own	4.73%	Short Float	0.70%	Perf Quarter	-84.50%
Sales	9.85M	P/S	0.24	EPS this Y	97.91%	Inst Trans	-77.17%	Short Ratio	0.18	Perf Half Y	-97.86%
Book/sh	51.92	P/B	0.01	EPS next Y	59.92%	ROA	-46.61%	Short Interest	0.02M	Perf Year	-99.29%
Cash/sh	0.48	P/C	1.55	EPS next 5Y	-	ROE	-79.55%	52W Range	0.69 - 110.00	Perf YTD	-99.15%
Dividend Est.	-	P/FCF	-	EPS past 5Y	22.72%	ROI	-80.81%	52W High	-99.32%	Beta	-0.33
Dividend TTM	-	Quick Ratio	0.31	Sales past 5Y	325.62%	Gross Margin	-23.47%	52W Low	8.62%	ATR (14)	0.24
Dividend Ex-Date	-	Current Ratio	0.32	EPS Y/Y TTM	50.07%	Oper. Margin	-330.27%	RSI (14)	35.95	Volatility	9.81% 10.68%
Employees	84	Debt/Eq	0.62	Sales Y/Y TTM	30.51%	Profit Margin	-323.34%	Recom	1.00	Target Price	5.00
Option/Short	No / Yes	LT Debt/Eq	0.54	EPS Q/Q	74.71%	Payout	-	Rel Volume	0.10	Prev Close	0.73
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	15.53%	Earnings	Aug 20 BMO	Avg Volume	107.17K	Price	0.75
SMA20	-5.03%	SMA50	-58.52%	SMA200	-97.77%	Trades		Volume	6,532	Change	2.60%

Oct-02-24 08:00AM	Scorpius Holdings Selected to Join Medical CBRN Defense Consortium to Advance Medical Countermeasures Against Chemical, Biological, Radiological, and Nuclear Threats (GlobeNewswire)
Sep-30-24 08:00AM	Scorpius Holdings Announces Contract with Premier Clinical-Stage Biotech Company; Opens Door to Future GMP Manufacturing Opportunities (GlobeNewswire)
Sep-12-24 08:00AM	Scorpius Holdings Commends the U.S. House of Representatives' Passage of the BIOSECURE Act (GlobeNewswire)
Sep-09-24 08:30AM	Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Medical Countermeasure Development in Support of BARDA (GlobeNewswire)
Aug-26-24 08:00AM	Scorpius Holdings CEO Provides Corporate Update; Highlights Expanding Sales Pipeline, Enhanced Manufacturing Capabilities, and Path Toward Positive Cash Flow (GlobeNewswire)
09:15AM	Loading…
Aug-20-24 09:15AM	Scorpius Holdings Achieves 16% Year-Over-Year Increase in Revenue for the Second Quarter of 2024 (GlobeNewswire) -10.52%
Aug-19-24 01:08PM	Scorpius Holdings, Inc. Announces Closing of Public Offering (GlobeNewswire) -12.84%
Aug-16-24 09:50AM	Scorpius Holdings, Inc. Announces Pricing of Public Offering (GlobeNewswire)
Aug-09-24 03:38PM	Scorpius Holdings, Inc. Provides Update on its Previously Announced Public Offering (GlobeNewswire)
Aug-06-24 08:45AM	Scorpius Holdings Weighted-Average Pipeline Surpasses $100 Million in Business Develop Opportunities Across Both Manufacturing Client and Government Sectors (ACCESSWIRE) +19.27%
08:16AM	Exclusive: Healthcare Service Provider Scorpius Surpasses $100M In Business Opportunities, Eyes Revenue Boost (Benzinga)

Scorpius Holdings, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SCPX

Scorpius Holdings Inc.

Upgrade your FINVIZ experience